ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,737Medicare Part D Prescriptions Filled, Including Refills

Rank: 341 out of 780

$323K Total Retail Price of All Prescriptions

Rank: 462 out of 780

577 Patients Receiving at Least One Drug in Part D
81%Patients 65 Years and Older
37% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Alabama
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

14% of this provider’s 577 patients filled at least one prescription for a schedule three drug, compared to an average of 19%.

Risky Drugs to Seniors

3% of this provider’s 6,871 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

20% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$37 was the average price of a prescription from this provider, compared to $51 among peers.

Prescriptions per Patient

15 is the average number of prescriptions (including refills) per patient, compared to an average of 23.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Alabama
LEVOTHYROXINE SODIUM 610 490 1 5
OMEPRAZOLE 395 283 2 3
AMLODIPINE BESYLATE 310 226 3 4
SIMVASTATIN 274 216 4 2
HYDROCODONE-ACETAMINOPHEN 263 166 S3 5 1
LISINOPRIL 216 168 6 6
PRAVASTATIN SODIUM 198 168 7 9
METFORMIN HCL 172 132 8 8
CITALOPRAM HBR 170 130 9 23
TRAMADOL HCL 136 101 10 15
METOPROLOL SUCCINATE 128 114 11 20
CIPROFLOXACIN HCL 118 103 12 49
DOXYCYCLINE HYCLATE 113 93 13 103
SERTRALINE HCL 113 89 13 27
FUROSEMIDE 111 82 15 7
GLIPIZIDE ER 111 94 15 109
METOPROLOL TARTRATE 104 82 17 19
AZITHROMYCIN 98 79 18 38
LOSARTAN-HYDROCHLOROTHIAZIDE 97 74 19 33
HYDROCHLOROTHIAZIDE 94 71 20 10
LISINOPRIL-HYDROCHLOROTHIAZIDE 89 78 21 26
ATORVASTATIN CALCIUM 89 70 21 12
GLIPIZIDE XL 88 62 23 176
CYMBALTA 85 35 24 51
WARFARIN SODIUM 83 82 25 24
LOSARTAN POTASSIUM 81 76 26 18
ZOLPIDEM TARTRATE 79 44 27 17
POTASSIUM CHLORIDE 77 53 28 11
PANTOPRAZOLE SODIUM 77 64 28 25
MELOXICAM 77 63 28 16
GABAPENTIN 74 47 31 13
BISOPROLOL FUMARATE 73 53 32 143
ATENOLOL 71 54 33 21
GLYBURIDE-METFORMIN HCL 71 50 R 33 108
ALENDRONATE SODIUM 71 68 33 44
TRAZODONE HCL 71 59 33 35
FLUOXETINE HCL 70 65 37 65
TRIAMTERENE-HCTZ 66 46 38 37
CLONIDINE HCL 63 63 39 28
AMITRIPTYLINE HCL 56 43 R 40 48
GLIMEPIRIDE 55 51 41 30
TRAMADOL HCL-ACETAMINOPHEN 54 53 42 140
MECLIZINE HCL 52 50 43 83
CLOTRIMAZOLE-BETAMETHASONE 51 42 44 166
ESCITALOPRAM OXALATE 50 40 45 61
VENLAFAXINE HCL ER 50 38 45 117
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 3, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.